EGFR and non-small cell lung carcinoma: Chee Khoon Lee has indicated that for NSCLC patients with EGFR mutation, those treated by immunotherapy did not possess any more significant survival benefits than those treated by chemotherapy in second and later lines of therapy (Lee et al. 2018).